Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DR10624 in Patients With Hypertriglyceridemia and Carotid Atherosclerotic Plaque
NCT07050134Enrolling by invitation
- Start
- Jul 2025
- Primary completion
- Dec 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Randomised, double-blind trial in hypertriglyceridemia and carotid atherosclerotic plaque (CAS) comparing DR10624 Injection with Placebo (2 arms). Primary endpoint: Change in carotid intima-media thickness at 24 weeks. Started Jul 2025; status: enrolling by invitation.
02
Drugs
DR10624
03
Conditions
hypertriglyceridemiacarotid atherosclerotic plaque (CAS)
Beyond the preview
Go deeper on NCT07050134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07050134.